These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23006047)

  • 1. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
    J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
    Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
    Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
    Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
    Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
    Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
    J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
    Abou-Zeid AA; Azzam AZ; Kamel NA
    Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of BRCA1 dysfunction to alter ovarian cancer survival.
    Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS
    Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
    Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
    Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
    McCoy ML; Mueller CR; Roskelley CD
    Reprod Biol Endocrinol; 2003 Oct; 1():72. PubMed ID: 14613551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
    Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
    Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
    Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
    J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
    Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microenvironmental regulation of BRCA1 gene expression by c-Jun and Fra2 in premalignant human ovarian surface epithelial cells.
    Zhou L; Graves M; MacDonald G; Cipollone J; Mueller CR; Roskelley CD
    Mol Cancer Res; 2013 Mar; 11(3):272-81. PubMed ID: 23339184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.